Article Information
History
- September 14, 2021.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.
Author Information
- Saki Takahashi1,*,
- Michael J. Peluso1,
- Jill Hakim1,
- Keirstinne Turcios1,
- Owen Janson1,
- Isobel Routledge1,
- Michael P. Busch2,3,
- Rebecca Hoh1,
- Viva Tai1,
- J. Daniel Kelly4,5,6,
- Jeffrey N. Martin4,
- Steven G. Deeks1,
- Timothy J. Henrich7,
- Bryan Greenhouse1 and
- Isabel Rodríguez-Barraquer1
- 1Division of HIV, Infectious Diseases & Global Medicine, University of California, San Francisco, USA
- 2Department of Laboratory Medicine, University of California, San Francisco, USA
- 3Vitalant Research Institute, San Francisco, USA
- 4Department of Epidemiology and Biostatistics, University of California, San Francisco, USA
- 5Institute for Global Health Sciences, University of California, San Francisco, USA
- 6F.I. Proctor Foundation, University of California, San Francisco, USA
- 7Division of Experimental Medicine, University of California, San Francisco, USA
- ↵*Correspondence to: saki.takahashi{at}ucsf.edu
Posted September 14, 2021.
SARS-CoV-2 serology across scales: a framework for unbiased seroprevalence estimation incorporating antibody kinetics and epidemic recency
